Q1 2025 Bio-Rad Laboratories Inc Earnings Call
Ladies and gentlemen, and thank you for standing by my name is desert rain I will be your conference operator today at this time I would like to welcome everyone to the bio Rad first quarter 'twenty twenty-five earnings results conference call and webcast all lines have been things on mute to prevent any background noise.
After the Speakers' remarks, there will be a question and answer session if.
If you would like to ask a question. During this time simply press star followed by the number one on your telephone keypad. If he would like to withdraw your question again press. The star one I would now like to turn the conference over to Edward Chang head of Investor Relations you may begin.
Speaker Change: Thanks, Steve.
Edward Chang: Good afternoon, everyone and thank you for joining us.
Edward Chang: Today, We will review the first quarter 2025 financial results and provide an update on key business trends for bio Rad.
Edward Chang: With me on the call today are Norman Schwartz, our Chief Executive Officer, John D, Vincenzo President and Chief operating Officer, and Luke <unk>.
Speaker Change: Michael Rajiv Executive Vice President and Chief Financial Officer before we begin our review I would like to remind everyone that we will be making forward looking statements about managements goals plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties.
Speaker Change: Our actual results may differ materially from these plans goals and expectations you should not place undue reliance on these forward looking statements and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward looking statements made during the call today.
Speaker Change: Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles investors should review. The reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.
Speaker Change: With that I'll now turn the call over to our Chief operating Officer, John Stephens Kenzo.
Speaker Change: Hello, and thank you for joining today's call despite a.
Speaker Change: Challenging macro environment with academic headwinds due to government funding and global trade disruptions from tariffs, we delivered solid Q1 results exceeding consensus for both revenue and operating margin.
Speaker Change: Our clinical diagnostics business performed slightly better than forecast, while our life science segment experienced softness in academia and Biopharma research, notably our bio production business saw positive momentum with year over year growth returning to our process chromatography business.
Speaker Change: We continue to prioritize bringing innovative products to our customers in Q1, we launched several key menu expansion for our core life science portfolio.
Speaker Change: Putting a new PCR based salmonella tests for food safety.
Speaker Change: I've been to our portfolio of <unk>, Barry check assays for cell and gene therapy.
Speaker Change: We are also strategically advancing droplet digital PCR is a valuable tool for oncology diagnosis and management through high valued assays and key partnerships.
Speaker Change: Recent compelling clinical trial data published in clinical cancer research.
Speaker Change: <unk> bio Rad DD PCR technology demonstrated a strong correlation between circulating tumor DNA changes in treatment outcomes in lung cancer.
Speaker Change: This highlights the significant impact of our <unk> platform on clinical decision, making and patient outcomes.
Speaker Change: Our team also demonstrated exceptional execution and driving productivity improvements and effective cost management building on our lean initiatives, we proactively evaluated and are implementing mitigation strategies for tariff impacts and response to escalating geopolitical and trade tensions.
Speaker Change: And diagnostics.
Speaker Change: We continued to show solid demand.
Speaker Change: Offsetting reimbursement reductions in China, with nearly 3% growth in the rest of the world.
Speaker Change: In life Science, we navigated academic and Biopharma research funding headwinds, particularly in the U S. While maintaining strong demand for consumables.
Speaker Change: Process chromatography, returning to growth as I have stated in our GDP you see our portfolio maintained its momentum and strong reagents and consumables growth.
Speaker Change: Our acquisition of <unk> technology remains on track for closing by the end of the third quarter. We are excited about the silver platform as it expands our offering in the digital PCR segment from gene expression to targeted rare mutation detection.
Speaker Change: We're planning a webinar following the close of the sale of transactions to outline our strategy and digital PCR with the addition of the Stella and continue on platforms.
Speaker Change: During the quarter I visited several of our global teams across three continents, including nine manufacturing sites and customer visits for both our life science and diagnostics segments.
Speaker Change: These visits reinforce my confidence in our team's commitment and strength of our global organization and fantastic relationships with our customers.
Speaker Change: Our investments in efficiency and productivity within our manufacturing sites and distribution centers are yielding tangible results.
Speaker Change: My travels, including a meeting with the leaders of the German Red Cross blood donation service, where we were recently awarded a multiyear contract renewal for our immuno hematology platform, a testament to the quality and reliability of our solutions.
Speaker Change: At <unk>, we continue to advance on our abilities to develop innovative products drive operational excellence and build upon our relationships with customers in over 133 countries.
Speaker Change: As we are laser focused on delivering sustainable profitable growth.
Speaker Change: We thank you for your ongoing support and I will now turn the call over to Ruth for a review of our financial performance.
Ruth: Thank you John and good afternoon, I'd like to start with a review of the first quarter of 2025 results.
Ruth: Overall, we executed well during the quarter, which allowed us to deliver revenue and operating profit and margin ahead of consensus estimates for Q1 net sales for the first quarter of 2025 were approximately 585 million, which represents a four 2% decline on a reported basis versus $611 million in Q1 of <unk>.
2024 on a currency neutral basis. This represents a one 5% year over year decrease was primarily driven by lower sales in our life Science group.
Ruth: Sales of life Science group in the first quarter of 2025 or $229 million compared to $242 million in Q1 of 2024, which is a decline of five 4% on a reported basis and three 5% on a currency neutral basis, primarily reflecting ongoing softness in the biotech.
Ruth: The academic research market, particularly in the Americas currency neutral sales decrease in the Americas and Asia Pacific, partially offset by increased sales in EMEA.
Ruth: Our process chromatography business experienced mid teens growth on a year over year basis. The strength in Q1 was due to the timing of customers orders and we continue to expect high single digit growth for this area in 2025.
Ruth: Excluding process chromatography sales core life Science group revenue decreased seven 5% year over year, and five 5% on a currency neutral basis due to the softness across the markets for instrument demand.
Ruth: Sales of the clinical diagnostics group in the first quarter of 2025 were approximate $357 million compared to $369 million in Q1 of 2024, which is a decrease of three 2% on a reported basis and effectively flat on a currency neutral basis.
Ruth: Increased demand for our quality control products was offset by the expected lower diabetes testing revenue and we currently do not expect further reimbursement changes in China. This year on a geographic basis currency neutral sales decreased in Asia Pacific, partially offset by <unk>.
Ruth: <unk> sales in EMEA and the Americas Q.
Ruth: Q1 reported GAAP gross margin was 52, 3% as compared to 53, 4% in the first quarter of 2020 for the decrease in gross margin was primarily driven by restructuring expenses related to the workforce reduction announced during the first quarter of 2025.
Ruth: SG&A expense for the first quarter of 2025 was 209 million or 35, 7% of sales compared to $215 million or <unk> 35, 2% in Q1 of 2020 for the.
Ruth: The decrease in SG&A expense was primarily due to lower discretionary spending and employee related costs, partially offset by restructuring costs.
Ruth: Research and development expense in the first quarter was $74 million or 12, 6% of sales compared to $66 million or 10, 9% of sales in Q1 of 2020 for the higher year over year R&D was primarily due.
Ruth: Due to restructuring costs, partially offset by lower employee related expenses.
Ruth: Q1, operating income was approximately $24 million or 4% of sales compared to $45 million or seven 3% of sales in Q1 of 'twenty for lower operating income is driven by higher restructuring costs, partially offset by the revenue mix continued proactive expense management initiatives.
Ruth: During the quarter interest and other income resulted in net other income of 28 million compare to the <unk>.
Ruth: Net other income of $24 million last year.
Ruth: The change in fair market value of equity security holdings, primarily related to the ownership of Sartorius AG shares cream attributed to our reported net income of $64 million or $2 29 per diluted share.
Ruth: The effective tax rate for the first quarter of 2025 was 23, 3% compared to 21, 8% for the <unk>.
Ruth: <unk> period in 2020 for the higher rate in 2025 was driven by our geographical mix of earnings.
Ruth: Moving to the non-GAAP results non-GAAP financial measures, which exclude certain atypical and unique items that impact both gross and operating margins and other income are detailed in the reconciliation table in our press release.
Ruth: First quarter non-GAAP gross margin was 53, 8% in line with consensus, but lower than Q1 2024 as results of 54, 2%.
Ruth: First quarter non-GAAP operating margin was 10, 8% compared to nine 7% in Q1 of 2024.
Ruth: The non-GAAP effective tax rate for the first quarter of 2024 was 26% compared to 22, 4% for the same period in 2024 at the lower rate in 2025 was driven by our geographical mix of earnings.
Ruth: Finally, non-GAAP net income for the first quarter 2025 was $71 million or $2 50 for.
Ruth: Diluted earnings per share.
Ruth: Moving onto the balance sheet.
Ruth: Total cash and short term investments at the end of Q1 were $1 $660 million compared to $1 $665 million.
Ruth: At the end of Q4 2020 for inventory at the end of Q1 was $790 million up from $760 million in the prior quarter.
Ruth: For the first quarter of 2025 net cash generated from operating activities was $130 million compared to $70 million for Q1 2024.
Ruth: Net capital expenditures for the first quarter of 2025 or.
Ruth: 34 million and depreciation and amortization for the first quarter was $38 million.
Ruth: Regarding free cash flow for the first quarter of 2025, we were pleased with the generation of $96 million, which compares to $30 million in Q1 of 2024, we continue to target full year cash flow free cash flow of approximately $310 million to $330 million for 2025.
Ruth: During the first quarter, we purchased 399295 shares of our stock for a total cost of $101 million or an average purchase price of approximately $253 per share in April we purchased an additional 422648 shares of our stock for a total cost.
Ruth: Cost of $99 million or an average purchase price of approximately $2 $234 per share.
Ruth: We will continue to be opportunistic with our buyback program and still have $377 million available for share repurchases under the current board authorized program.
Ruth: Moving on to the non-GAAP guidance for 2025, we are updating our 2025 full year guide to reflect the Q1 results the evolving state of the academic and biotech research funding and the impact of recent changes in the macro economy, including tariffs.
Ruth: We recognize that the recent macro changes are causing uncertainty and remain fluid. However in the interest of full transparency, we are providing our best estimates of the impact of the known changes as of today. Overall, we now expect total currency neutral revenue to be in the range of approximately a 1% decline to one five.
Ruth: Percent growth or approximately 225 basis points lower than our previous guidance.
Ruth: I'll start with the effect of the softer academic research funding as a result of the changes in U S policy.
Ruth: We now expect these life science purchases to be more muted in 2025 in particular demand for instruments as customers evaluate the impact of potential changes to government funding. We are also seeing reduced demand from biotech customers, particularly among small and mid sized development stage companies that have become.
Ruth: More conservative with equipment spending due to the increased volatility in the capital markets as.
Ruth: As such we now expect our life science business to be in the range of flat to down 3% for the full year versus a growth of approximately one 5% to three 5% previously.
Ruth: Next we are de risking our diagnostics growth outlook by approximately 100 basis points to reflect a softer macroeconomic environment, particularly in China, and now anticipate full year growth of approximately 5% to two 5%.
Ruth: The net effect of the market softness in our business group is approximately a 100 basis point headwind to operating margin.
Finally, the impact of tariffs.
Our updated guidance considers tariffs that are in effect globally as of today and assumes no change in the current U S policy. The net impact of the tariffs is 130 basis point headwind to operating margin primarily due to a U S manufactured products that are imported into China, Inc.
Ruth: Included in this updated view of our actions we are taking to partially mitigate the effects of the tariffs tariffs such as surcharges pre positioning inventory in certain countries further regionalized supply chains and identifying additional in region manufacturing opportunities.
Ruth: Factoring in the above the updated full year non-GAAP gross margin is projected to be between 53 and 54, 5%.
Ruth: Note that we were able to offset the impact from market softness through our actions and the difference relative to our prior full year gross margin outlook of $55 to 55, 5% is entirely due to the impact of tariffs.
Ruth: Full year non-GAAP operating margin is projected to be between 10 and 12% included in this range are the above considerations that I just spoke up. Additionally, we continue to be on track to achieve our key development milestones in Q3 2025 related to sabre buyout, which as discussed previously would result in a onetime in process R&D charge.
Ruth: A $10 million.
Ruth: As a result of the recent weakening U S. Dollar, we expect less of a headwind to our revenue and operating income than our prior guidance. We now expect approximately a 100 basis point headwind to 2025 revenue and approximate 20 basis point impact on operating margin versus the prior 40 basis point effect.
Ruth: We estimate the non-GAAP full year tax rate to be approximately 22 versus 23% previously due to the change in the equity value of sertorius investment.
Ruth: With our updated outlook for 2025, we recognize that there are many moving pieces and the situation is evolving rapidly. There is a wide range of scenarios that could ultimately play out.
Ruth: That said, we're trying to be prudent and transparent in providing the key headwinds that we are currently seeing in the marketplace, where possible. We are focused on mitigating the impacts from proposed tariffs and global trade disruptions to deliver results for shareholders as you've seen in the past year management's approach to guidance is to be realistic in setting expectations.
Ruth: <unk>.
Ruth: While we are adjusting our 2025 outlook. This does not shift our focus from the significant opportunities we see in enhancing business performance driving consistent top line growth remains central to our strategy and a key enabler of substantial margin expansion.
Ruth: We are confident that our ability to improve operational efficiency and strategically optimize our footprint will allow us to capture hundreds of basis points of margin expansion over the coming years, we're eager to share more about this opportunity and other critical aspects of our business at our Investor Day. This fall.
Ruth: I'll now turn the call over to Norman for his remarks.
Norman: Okay. So.
Speaker Change: I think as <unk> alluded to.
Norman: We continue to operate in what.
Norman: What I think of let's say in a very dynamic environment.
Norman: And I would say that in all my years in this business I have never experienced such a prolonged period of.
Norman: Macro economic headwinds.
Norman: And their impact on the growth of our business I would say, especially for for life science.
Norman: However.
Norman: We are still in the Golden age of biology, and I continue to see a long runway ahead for for life Science research and diagnostics at two principal markets that we serve.
Norman: We remain committed to our customers.
Norman: <unk> markets that we serve.
Norman: And certainly the contributions we can make which positioned by our AD for consistent profitable growth.
Norman: Second I would say that with our strong balance sheet.
Norman: We have tremendous optionality.
Norman: We continue to invest in our business, we remain active in evaluating.
Norman: Inorganic opportunities.
Norman: Opportunities that potentially offer values to customers immediately.
Norman: With the increased volatility in the equity market in the past few months.
Norman: We are seeing more opportunities as valuations for assets have moderated.
Norman: Private sector, where they have been in recent years.
Norman: And finally, I guess I would note that <unk> has been resilient.
Norman: And has persevered through many cycles in our 70 plus year history.
Norman: To the credit and determination of <unk> employees around the world.
Norman: Continued to advance our corporate transformation and believe we'll come through this dynamic period, even stronger than before.
Norman: So add that that's all I have to turn it back to you and that concludes our prepared remarks and now we'll open the line to take your questions operator.
Speaker Change: Thank you we will now begin the question and answer session. If you have dialed in and we'd like to ask a question. Please press star one on your telephone keypad to raise your hand in China Q. If you would like to withdraw your question simply press Star. One again, if you are called upon to ask a question in a listening via speaker. Following your device. Please pick up your handset.
Speaker Change: Thanks sure that your phone is not on mute when asking a question again press star one to join the queue.
Speaker Change: And our first question comes from the line of Patrick Donnelly with Citigroup. Your line is open.
Patrick Donnelly: Hey, guys. Thank you for taking the questions.
Speaker Change: Probably one for you to start.
Patrick Donnelly: Rising tariffs.
Patrick Donnelly: It sounds like you guys are layering in some impact into the guide can you just talk about maybe the gross impact what mitigation efforts you guys are doing it sounds like potential surcharges I am sure some acceleration on the cost side and what's the ability to contain this impact into 2025 some of it linger, maybe just walk us through what Youre seeing.
What the mitigation efforts are and how to think about this.
Speaker Change: Of course, thanks, Patrick for the question.
Patrick Donnelly: Not surprising also in terms of leading off with tariffs right.
Patrick Donnelly: So there are a number of factors, let let's step back first of all maybe just to understand where the tariff impacts are coming from I think theres a few different aspects one is.
Patrick Donnelly: Our global footprint is a positive for us. However, we don't have China manufacturing footprint today. So that's one consideration here, where the tariffs are most significantly impacting us is obviously U S products being shipped into China, but also Europe products that are being shipped into the U S and so.
Patrick Donnelly: We're very mindful of that and then there is a core supplier considerations as we think about these different tariff pieces.
Patrick Donnelly: We are taking actions in terms of potential surcharges as I've mentioned in my prepared remarks, but we also have been seeking to preposition inventory.
Patrick Donnelly: And that's been another aspect of it the other pieces of this are longer term right in terms of looking at in region manufacturing opportunities. But also then how do we drive further supply chain.
Patrick Donnelly: Vitality in region as well in support of the manufacturing and so all of these but those last two that I just mentioned are longer term in nature, and especially for our diagnostics part of the business, which as you think about the regulatory considerations, it's a multi year journey and so as we think about.
Patrick Donnelly: The gross margin and operating margin effect here.
Patrick Donnelly: The gross margin as I mentioned movement from the original guide is effectively all tariff related we were able to mitigate the operational softness we're saying sorry market softness we are seeing.
Patrick Donnelly: And so when you think about that it's how can we look at within 2025 any further actions, we can take and we will seek to limit. It to 2025. However, I think it's still a fluid environment and so it's hard to say what 26 might hold at this point in time.
Patrick Donnelly: Okay. That's helpful and then just the academic side.
Patrick Donnelly: Obviously, that's worrisome here over the past past couple of months what have you guys seen as we work our way through March and April obviously, the IH proposal came out at 40% cut what's the expectation now for academic and again, maybe just the cadence of what you saw as we worked our way through the quarter and into April on that segment would be.
Patrick Donnelly: Would be helpful.
Speaker Change: Yes, maybe maybe I can start and then have Norway and John jump in as well.
Speaker Change: I think what we saw in and Theres been some recent article is just on level of funding decrease that's occurred there was something that came out more recently in the last day or two talked about a 28% reduction in overall funding.
Speaker Change: I think through the first quarter, we were able to hold and especially because of consumables.
Speaker Change: Were maintained to be fairly strong it really is the instruments, where we saw the softness more so.
Speaker Change: But it it worsened as we had gone through Q1 and as we think about where we are in Q2 and moving forward I think the continued.
Speaker Change: Lack of clarity on what is the funding level Where's the.
Speaker Change: Threshold is going to be maintained what level of funding is going to be provided that's creating some some additional challenges for people from.
Speaker Change: And activity standpoint, we're still seeing consumables activity, our activity and especially on the consumable side. It's the instrument side that continues to be challenging.
I think for us at this point in time.
Speaker Change: Okay, and maybe lastly, so yes.
Speaker Change: Yes.
Speaker Change: Go ahead.
Moderator: Our next question comes from the line of Dan Leonard with UBS. Your line is open.
Dan Leonard: Thank you maybe just to rip off that last question. There how wide is the gap at this point in growth between consumables and equipment.
Dan Leonard: I would say, it's been a bit of a deterioration if I just look at it sequentially in terms of the instruments.
Dan Leonard: Sure.
Dan Leonard: Sales on a sequential basis, Dan, it's probably down about 10% further decline consumables actually had held up fairly well from a sequential standpoint in Q1 versus Q4, maybe just tad down but still very strong overall hopefully that gives you the ad.
Dan Leonard: Our perspective Youre seeking.
Dan Leonard: That's helpful and then as a follow up.
Dan Leonard: I could use a little bit more help understanding exactly the tariff exposure. So a couple of specific questions. What proportion of your revenue in China is sourced from the U S. What percentage of your revenue in the U S is sourced from the U S and this insulated from Europe or China tariffs.
Dan Leonard: And what assumption are you, making regarding who.
Dan Leonard: Who each the tariffs how much are you off setting with a surcharge versus absorbing the tariffs on your P&L.
Dan Leonard: Yes, so so.
Dan Leonard: Again, we don't have any China manufacturing right. So thats first and foremost to understand so you can imagine that.
Speaker Change: The revenue.
Speaker Change: Going into China is either coming from the U S or Singapore predominantly or there is a bit in Europe, as well and the biggest piece of the tariff impact as those pieces, obviously coming from the U S into.
Speaker Change: China and especially.
Speaker Change: On the diagnostics side of the house and so that's where we're seeing the largest impact of.
Speaker Change: Of the tariffs overall in terms of what we've articulated.
Speaker Change: And then your assumption on.
Speaker Change: Observe that tariff on your P&L.
Speaker Change: Yes, I mean, I think it's something we are evaluate obviously, we talked about surcharges that were putting in place.
Speaker Change: And we're working through that and have deployed that already but as we think about how things are evolving I think we're also mindful of.
Speaker Change: How the situation is evolving on a geographic basis.
Speaker Change: Especially in China with the U S. Specifically.
Speaker Change: Okay. Thank you we are prepared to put in some price adjustments and surcharges.
Speaker Change: Nearly effective immediately.
Speaker Change: On the diagnostics side, we have longer term contracts, which do have some ability to adjust but not exactly the same as in life Sciences.
Speaker Change: The team is kind of just preparing how could we compensate for the tariffs.
Speaker Change: If we can absorb it observe it otherwise.
Speaker Change: Tying that in additional charges to customers.
Speaker Change: Okay. Thank you. So just one more thing to keep in mind that it's.
Speaker Change: Yes.
Speaker Change: The tariff surcharges.
Speaker Change: A free ride.
Speaker Change: Many of these customers have limited budgets so to the extent you have a tariff surcharge you might reduce the.
Speaker Change: The amount of purchases that are made.
Speaker Change: Yes, I was wondering that as well Norman thank you.
Brandon Couillard: Next question comes from the line of Brandon Couillard with Wells Fargo. Your line is open.
Brandon Couillard: Hey, Thanks, I want to follow up on that line of questioning so as it relates to.
Speaker Change: Product, you're shipping to China, and some of your peers have assumed that.
Speaker Change: That revenue just goes away and Scott is that feasible for customers to buy the product or have you assumed demand destruction and are the surcharges on terms of like topline embedded in the guidance.
Speaker Change: As of right now.
Speaker Change: So two pieces there Brandon in terms of the ladder the surcharges are embedded.
Speaker Change: Consideration of the surcharges that are embedded within the guide.
Speaker Change: In terms of the former.
Speaker Change: We are looking at it from a so we're not looking at where we are looking at it from the standpoint of preserving customer continuity and market share and therefore, we are seeing it as strategic in terms of if we are considering the tariff situation.
Speaker Change: <unk> how fluid it is.
Speaker Change: Where surcharges ought to be applied and how we ought to do that.
Speaker Change: But again initiatives.
Speaker Change: <unk> alluded to earlier.
Speaker Change: The products going into China actually come from.
Speaker Change: Not just the Americas, but.
Speaker Change: From Europe and from Asia.
Speaker Change: Specifically, Singapore, so so we've got that we've got.
Speaker Change: A reasonable amount of mitigation.
Speaker Change: <unk> of <unk>.
Speaker Change: China tariffs.
Speaker Change: Sure.
Speaker Change: For those products.
Speaker Change: Okay.
Speaker Change: In terms of the guide.
Speaker Change: Based on where you came in in the first quarter. It still seems to imply a big second half ramp, especially when youre looking at it on a on a two year stacked comps.
Speaker Change: So can you just help us understand to what degree DDG de risks the topline outlook enough.
Speaker Change: The back half.
Speaker Change: Boy I mean.
Speaker Change: That is the <unk>.
Brandon Couillard: Isn't that Brandon I mean, we've tried to take a conservative view.
Speaker Change: The demand profile.
Brandon Couillard: And how we see that softness.
Brandon Couillard: The ramp from Q1 to Q2 and Q2 Q3 are relatively flat.
Brandon Couillard: There is a little bit of uptick in Q4, but we've also and there are some specific nuances too.
Brandon Couillard: Let's face it <unk> or is it part of it's seasonality part of it.
Brandon Couillard: Some quality systems.
Brandon Couillard: Revenue that we see uptake process chrome continues relatively consistent through the year. So we've tried to de risk. It in terms of these moving pieces.
Brandon Couillard: I think we've.
Brandon Couillard: As we've tried to be over the course of the last year or so be reasonable in terms of our point of view.
Brandon Couillard: Yeah.
Brandon Couillard: While while really taking a prudent approach on what we're seeing in the marketplace.
Brandon Couillard: And yes it does.
Brandon Couillard: We're obviously very closely with the commercial team's here looking at number of proposals win rate sales cycle and then the run rate business run rate business has continued to be.
Brandon Couillard: As modeled.
Brandon Couillard: The run rate as you can imagine on the instrument side of things the sales cycles are longer although weak maintain our win rate, which is a positive.
Brandon Couillard: We believe that things will settle down here in the coming months.
Brandon Couillard: A couple of quarters and.
Brandon Couillard: <unk> is pretty optimistic on the current forecast.
Brandon Couillard: Capability.
Brandon Couillard: Yes.
Brandon Couillard: Okay last one Norman you mentioned the balance sheet Optionality.
Brandon Couillard: Availability of assets valuations, which is helpful.
Speaker Change: Update us on your your priority of your preference for capital allocation right. Now you are buying back a lot of stock which.
Brandon Couillard: Which is great.
Brandon Couillard: Would you consider a larger deal perhaps right now thats may be north of $1 billion or are you primarily still focused on bolt ons, where your preferences, yes.
Brandon Couillard: Yeah, Yeah, I think especially given some of the.
Brandon Couillard: Given some of the what I think of is attractive inorganic opportunities that are that are bubbling up.
Brandon Couillard: I think there is there is a real appetite for doing something meaningful.
Brandon Couillard: Obviously.
Brandon Couillard: Honestly the right deal is important for us.
Brandon Couillard: Especially those largest haynesville provide scale.
Brandon Couillard: We can leverage our kind of global.
Brandon Couillard: Global commercial operations.
Brandon Couillard: Yes lots of things, we could do there, but I think we are focused a little bit on on larger things and yes, we've got plenty of.
Brandon Couillard: And our capacity.
Brandon Couillard: On our balance sheet.
Brandon Couillard: And certainly do something in the in the <unk> range.
Brandon Couillard: Thank you.
Brandon Couillard: Thanks Brendan.
Speaker Change: Our next question comes from the line of Tycho Peterson with Jefferies. Your line is open.
Speaker Change: Hey, this is Matt on for Tycho, maybe just to start on Biopharma group I think you talked about kind of softer trends on smaller and midsized, obviously process chrome up mid teens in <unk> good to see I guess on process chrome.
Speaker Change: Is there any kind of initial early year stocking.
Speaker Change: Comps there why wouldn't that trend.
Speaker Change: Relative to the high single digit guide and then in terms of consumables versus instruments within Biopharma and maybe more specifically the droplet digital PCR has your outlook changed at all for the year in terms of consumables and instruments.
Speaker Change: Within that end market. Thanks, yes.
Speaker Change: Yes, Thanks, Matt.
Speaker Change: About Amazon.
Speaker Change: So in terms of buyer processing to start with.
Speaker Change: Process Chrome was was a positive for us it was nice to say to your question of why shouldn't that continue.
Speaker Change: It really is and we didn't pull anything forward, but customer demand drove it such that they wanted some uptake earlier in Q1 than what we would have otherwise wanted a little later for their own from their own manufacturing production standpoint, we still see it as a high single digit growth for the year.
Speaker Change: And really just as we've expected that Destocking has continued to decrease and it's normalizing as we would expect so nothing unusual there.
Speaker Change: It's very much a positive there for us in terms of your question on consumables and instrumentation.
Speaker Change: The real softness is really around instrumentation and thats the biggest challenge for us.
Speaker Change: <unk> has held fairly nicely.
Speaker Change: Even considering kind of the macro around academia NIH et cetera.
Speaker Change: And so we're happy to see that but where where the softness we pulled it back is specifically related to academia and biotech if you will.
Speaker Change: And the instrumentation side of that.
Speaker Change: Okay. Thanks, and then just wanted to clarify I think you had baked in prior $15 million for the year on the reimbursement dynamics in China, I guess just to clarify did those kind of play out as expected in <unk> in any way you can kind of quantify what the reimbursement headwinds was tier two or China.
Speaker Change: Here in the first quarter.
Speaker Change: You said it well.
Speaker Change: Played out just as we expected nothing different.
Speaker Change: Nothing incremental and just in terms of that number that you quoted just now the $15 million can you just think of that as well.
Speaker Change: One quarter value of that is kind of played out effectively.
Speaker Change: Okay. Thanks, and maybe just one more understand you still haven't closed the deal.
Speaker Change: Human remains on track for the third quarter, but just any kind of color or update in terms of conversations you've had with customers now that it's been some time since you've announced it.
Speaker Change: If you could give a strategy update here in a few months, but just any feedback or color from from your customers since you've kind of announced the deal maybe excitement levels around that any more color to add around the stihler acquisition. Thank you, yes, I think first of all within our teams and I mentioned that kind of <unk>.
Speaker Change: Travel the globe during the quarter and each of our teams are very excited about the platform and what we can do with our content on that platform.
Speaker Change: Even into the food application applied applications. So we.
Speaker Change: We remain very excited about it.
Speaker Change: We haven't been jumping the gun and engaging customers necessarily on certain things, but where it has come kind of across in certain areas. There is very positive feedback.
Speaker Change: I was really surprised that the brand awareness that's out there on the platform in various geographies around the globe. So we're bullish.
Speaker Change: We still have a little ways to go here before we close the deal and can really kind of engage with customers, but overall there is a lot of excitement.
Speaker Change: And it's.
Speaker Change: I think that the.
Speaker Change: Same thing as the ease of use and the workflow of that platform.
Speaker Change: He is very very exciting to see.
Speaker Change: The marketplace.
Speaker Change: Great. Thank you.
Speaker Change: Pat.
Speaker Change: Next question comes from the line of Conor Mcnamara with RBC capital markets. Your line is open.
Conor Mcnamara: Hey, guys. Thanks for taking the questions just first one on the life Science business can you talk about the dynamics there first on the pull forward.
Speaker Change: Process CRO.
Speaker Change: Was any of that ahead of tariffs.
Speaker Change: What can you comment on the strength of that and kind of the cadence of that through that through the year, maybe we'll start there.
Speaker Change: Yes, so cotter I wanted to clarify it wasn't necessarily a pull forward by us it's something that was customer demand driven right in terms of it and we don't think it was tariff related it wasn't tariff of lifestyle. It wasn't a pre positioning of that revenue ahead of tariffs or anything like that.
Speaker Change: Okay. Thanks for that and then the team is basically confirm their full year forecast as we submitted and that's pretty solid as a very solid forecast.
Speaker Change: Okay, Perfect and then if my math is right it looks like you've taken about $40 million out of the life science.
Speaker Change: Guide, which.
Speaker Change: I think you've said that the federally funded academic and government sales was 4% of your sales.
Speaker Change: Is that $40 million, all coming out of that and kind of are you make any assumption that will be down 40% year over year or is there anything else baked into the life science cut yes.
Speaker Change: Yes.
Speaker Change: It really is so you are right. The federally funded slash NIH you said as you said, it's as we said before 4% remember academia broadly as a larger percentage of our overall revenue somewhere in that let's call. It twentyish percent. So.
Speaker Change: That's the other piece of that.
Speaker Change: That comes into play right overall.
Speaker Change: And the other piece is as a fee.
Speaker Change: Function of that geographically, China continuing to be soft.
Speaker Change: From a macro and jeff's situation standpoint.
Speaker Change: In the first quarter.
As you've probably seen counter there were 456 week period of time, there in February and March where there were almost no grants approved a renewed so it was pretty dramatic impact there, we won't see that probably until a number of quarters from now.
Speaker Change: And it may be a little more dramatic in the first quarter, then we're going to see the rest of the year, but theres certainly softness in concerned by our customers.
Speaker Change: Yes, I mean, hopefully that that will.
Speaker Change: We go through the year that will go away.
Speaker Change: That will moderate that.
Ted: Hey, Ted.
Speaker Change: Debt.
Speaker Change: Cautiousness will moderate.
Speaker Change: We still haven't seen Congress weigh in on the <unk>.
Speaker Change: NH going forward so.
Speaker Change: Got it and we will have to see how that goes.
Speaker Change: Got it okay. Thanks for that and then just last one for me you said you've de risked your clinical diagnostics growth by 100 basis points does that is that just conservatism.
Speaker Change: Weaker demand ahead of <unk> because of what's going on in the macro environment or is there anything that you saw.
Speaker Change: Within the quarter.
Speaker Change: Excellent in the quarter that would imply that that 100 basis points cut is what youre actually seeing it just sounded like youre, just taking a conservative tone on that if you could give more color I appreciate it well I mean again, let's keep in mind I think it's the macro from a Dx standpoint.
Speaker Change: Activity levels.
Speaker Change: As one aspect of it China is another aspect of it and China may be the more significant aspect of it right.
Speaker Change: And so those those are the pieces and just.
Speaker Change: Knock on wood, we haven't seen any further reimbursement rate changes or anything like that GBP hasnt been anything to note for us.
Speaker Change: And so it really is just the macro dynamics and softness.
Speaker Change: And our next question comes from the line of Jack Meehan with Nephron Research. Your line is open.
Jack Meehan: Thank you good afternoon, everyone.
Speaker Change: Afternoon.
Speaker Change: Wanted to start just a follow up on the tariff assumptions here. This 130 Bip op margin impact so it's about $30 million to EBIT.
Speaker Change: First just wanted to confirm is this a three quarter impact you're assuming for the reciprocal tariff.
Speaker Change:
Speaker Change: And are you assuming any revenue impact or is it really just like the increased cost on exports for those products.
Speaker Change: So so it really depends on which tariffs are in place so its respective due to the tariffs and play obviously there are certain tariffs that have a pause right now some are in effect already so that's what's contemplated in terms of that guide what we also did we also determined as the.
Speaker Change: Surcharges is a net effect of that.
Speaker Change: Within that overall guide.
Speaker Change: Okay.
Speaker Change: And then.
Speaker Change: You mentioned for that within the diagnostics business some of them a few times you've mentioned.
Speaker Change: Part of it is related to the China region.
Speaker Change: Can you just talk about how China diagnostics did overall for bio Rad and the first quarter.
Speaker Change: And do you think could be increased.
Speaker Change: Like is that like what you're referring to in terms of the macro or is it something broader there.
Speaker Change: Well a good portion of our.
Speaker Change: Diagnostic business in China is actually the quality systems, which we're trying to understand clearly whether that's going to be.
Speaker Change: Excluded from tariffs or not so it looks like Thats a good news for us.
Speaker Change: I don't think its exact numbers with us.
Speaker Change: Yes, I mean, if you think about China overall for us Jack.
Speaker Change: It was kind of mid single digits, let's call. It mid to high single digits kind of effect negative effect from what we had expected in China.
Speaker Change: And overall I would say it got tougher as we went through the quarter.
Speaker Change: And I think that's the other aspect to keep in mind.
Speaker Change: Got it okay.
Speaker Change: And then just the last one but the free cash flow update was a bright spot kind of maintaining that forecast despite.
Speaker Change: The lower op margin can you just talk about like some of the.
Speaker Change: Levers you're pulling is it working capital just what else Youre looking at.
Speaker Change: Deliver on free cash flow.
Speaker Change: It really is the working capital I mean, we continue to focus on inventory and inventory management, obviously with the forecast changes were running that through the system and looking at what else. We can do in region in terms of the timing of those the other aspect is looking at <unk>.
Speaker Change: Supplier management as well as our DSO in terms of opportunities for improvement there. So we have specific initiatives on all of those fronts.
Speaker Change: We're in it gives us confidence to.
Speaker Change: Still stand behind the free cash flow range that we provided.
Speaker Change: Okay. Thank you Rick.
Speaker Change: Yes.
Edward Chang: That concludes the question and answer session I would like to turn the call back over to Edward <unk> for closing remarks.
Edward Chang: Thank you for joining today's call will be participating at the RBC Global Healthcare Conference in New York later this month and will also be back out in New York in early June for the Jefferies Global Healthcare conference as always we appreciate your interest and we look forward to connecting soon.
Edward Chang: Alright.
Ladies and gentlemen, this concludes today's conference call. Thank you all for joining and you may now disconnect.
Edward Chang: [music].
Edward Chang: Yes.
Edward Chang: [music].
Edward Chang: [music].
Edward Chang: Okay.